Clearside Biomedical (STU:CLM0) PEG Ratio: N/A (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CLM0 Clearside Biomedical Inc STU:CLM0
49 GF Score
Price €4.35
GF Value €110.06
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Clearside Biomedical's PE Ratio without NRI is 0.00. Clearside Biomedical's 5-Year EBITDA growth rate is 0.00%. Therefore, Clearside Biomedical's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Clearside Biomedical's PEG Ratio or its related term are showing as below:



STU:CLM0's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.895
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Clearside Biomedical  (STU:CLM0) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Clearside Biomedical PEG Ratio Related Terms


Clearside Biomedical PEG Ratio Historical Data

* Premium members only.

The historical data trend for Clearside Biomedical's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearside Biomedical PEG Ratio Chart

Clearside Biomedical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 6.58 0.00 0.00 0.00

Clearside Biomedical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:CLM0 vs RMTG, ABPO, SCNI: PEG Ratio Comparison

For the Biotechnology subindustry, Clearside Biomedical's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's PEG Ratio falls into.


STU:CLM0
49GF Score
Clearside Biomedical Inc STU:CLM0
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clearside Biomedical PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Clearside Biomedical's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Clearside Biomedical (STU:CLM0) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of €4.35 is trading 96% below its estimated GF Value™ of €110.06.

Key valuation signals for STU:CLM0:

  • PEG Ratio: N/A
  • GF Value™: €110.06 vs. price of €4.35 (96% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the STU:CLM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clearside Biomedical Business Description

Other Exchanges CLSDQ:USA
Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score

Get the complete analysis for STU:CLM0

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.35
Price
€110.06
GF Value